It is proposed that by allowing urological surgeons access to laboratory markers such as HER-2, Thrombomodulin, CEACAM-1 and CD31, potentially, in the future, these biomarkers may be used in addition to, or in combination with, currently used scoring systems to predict cancer recurrence and progression. Here, THBD is linked to cancer.